DEFENCE'S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED
OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS

EQS-News: Defence Therapeutics Inc. / Key word(s): Study
DEFENCE'S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED
OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS

25.06.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

Vancouver, BC, Canada, June 25th, 2024 - Defence Therapeutics Inc.
("Defence" or the "Company"), a Canadian biopharmaceutical company
developing novel immune-oncology vaccines and drug delivery technologies, is
pleased to announce that its second-generation ARM-X anti-cancer vaccine is
therapeutically effective against pre-established ovarian cancer (ID8 model)
when combined with the anti-PD-1 immune-checkpoint inhibitor.

Using Defence's Accum® platform, the Company previously demonstrated that
AccuTOX® treatment of MSCs results in the induction of antigen
cross-presentation capacity (ARM-X cells), which can mount potent
anti-tumoral responses in animal pre-clinical models. This was previously
achieved using various cancer models including solid T-cell lymphoma,
melanoma and pancreatic cancer. Defence just completed an additional study
where animals with pre-established ovarian cancer responded to a combination
therapy including ARM-X and anti-PD-1. The latter group prolonged animal
survival beyond 80 days post-vaccination, and it led to a complete response
in almost all treated animals as shown in Figure 1.

"This is the 4th cancer model that we efficiently targeted using our ARM-X
antic-cancer vaccine. The purpose of testing our vaccine in various models
is to highlight how ARM-X can be adapted to the needs of any patient, no
matter the type of cancer, given that we have access to a tumor biopsy."
says Mr. Sebastien Plouffe, Chief Executive Officer of Defence Therapeutics.

One of the major advantages of Defence's ARM-X vaccine is the need of lower
antigen amounts to manufacture the vaccine. This is important as it avoids
the need of a big tumor sample in the vaccine generation. Defence is
currently testing its ARM-X vaccine on colon as an additional indication.
These results will set the target indication for the Phase I-IIa trials, and
it also shows how versatile and adaptable can the ARM-X anti-cancer vaccine
be.

About Defence:

Defence Therapeutics is a publicly-traded clinical-stage biotechnology
company working on engineering the next generation vaccines and ADC products
using its proprietary platform. The core of Defence Therapeutics platform is
the ACCUM® technology, which enables precision delivery of vaccine antigens
or ADCs in their intact form to target cells. As a result, increased
efficacy and potency can be reached against catastrophic illness such as
cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

Splouffe@defencetherapeutics.com

www.defencetherapeutics.com

https://www.linkedin.com/company/defence-therapeutics

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking
statements". All statements in this release, other than statements of
historical facts, that address events or developments that the Company
expects to occur, are forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not
always, identified by the words "expects", "plans", "anticipates",
"believes", "intends", "estimates", "projects", "potential" and similar
expressions, or that events or conditions "will", "would", "may", "could" or
"should" occur. Although the Company believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance and actual results may
differ materially from those in the forward-looking statements. Factors that
could cause the actual results to differ materially from those in
forward-looking statements include regulatory actions, market prices, and
continued availability of capital and financing, and general economic,
market or business conditions. Investors are cautioned that any such
statements are not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on the
beliefs, estimates and opinions of the Company's management on the date the
statements are made. Except as required by applicable securities laws, the
Company undertakes no obligation to update these forward-looking statements
in the event that management's beliefs, estimates or opinions, or other
factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or accuracy of
this release.


---------------------------------------------------------------------------

25.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Defence Therapeutics Inc.
                   1680 - 200 Burrard St
                   V6C3L6 Vancouver
                   Canada
   E-mail:         info@defencetherapeutics.com
   Internet:       https://defencetherapeutics.com
   ISIN:           CA24463V1013
   WKN:            A3CN14
   Listed:         Regulated Unofficial Market in Frankfurt, Stuttgart;
                   Toronto
   EQS News ID:    1931953

End of News EQS News Service
---------------------------------------------------------------------------

1931953 25.06.2024 CET/CEST